Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Conditions: Blasts Under 5 Percent of Peripheral Blood White Cells; Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level; IDH2 Gene Mutation; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia Interventions: Drug: Enasidenib; Procedure: Hematopoietic Cell Transplantation Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Genetics | Leukemia | Research | Transplants